Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Published byFanny Gunardi Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability."— Presentation transcript:

1 Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. Kaplan–Meier curves for time to clinical stability and time to defervescence in patients with pneumococcal pneumonia treated with rifampicin versus patients treated without rifampicin. Filled circles, β-lactam without rifampicin; open circles, rifampicin with β-lactam. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact J Antimicrob Chemother, dkz207, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Biomarkers in patients’ plasma before, during and after treatment. The inflammation biomarkers CRP, PCT and ... Figure 2. Biomarkers in patients’ plasma before, during and after treatment. The inflammation biomarkers CRP, PCT and MR-proADM were analysed in plasma. Median biomarker with IQR over time for patients with pneumococcal pneumonia (a–c) and for all patients (d–f). Filled circles, β-lactam without rifampicin; open circles, rifampicin with β-lactam. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact J Antimicrob Chemother, dkz207, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Heatmap of RNA expression results measured by MLPA in all patients. Heatmap at time = 24 h for ... Figure 3. Heatmap of RNA expression results measured by MLPA in all patients. Heatmap at time = 24 h for rifampicin-treated patients (brown) versus patients treated without rifampicin (green). Clustering is poor for all genes investigated irrespective of clinical diagnosis. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact J Antimicrob Chemother, dkz207, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 3: Full-body skeletal scintigraphy.

Figure 3: Full-body skeletal scintigraphy.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion

Similar presentations

Ads by Google